ClinicalTrials.gg
CompletedNCT02079909Updated Feb 26, 2019Results posted

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

A Phase 2 interventional study of T-817MA-H and T-817MA-L in Alzheimer's Disease, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 50 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
189th of 1,610
482 · median 73
Started
2014
with 53 others
Phase 2
360 of 1,941
50 open now
Registered
629th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 189th largest by enrollment of the 1,610 interventional ones that give a count, is one of 54 that started in 2014, is one of 360 in phase 2, and was the 629th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.

The secondary objectives are:

  • To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories, physical examinations, ECGs and solicitation of adverse events.
  • To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric Inventory (NPI) and Mini-mental State Examination (MMSE).
03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Alzheimer's
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ( or surgically sterile)
  • Patients with Mild to moderate Alzheimer's disease who are receiving donepezil (Aricept®) or rivastigmine transdermal system (Exelon® Patch), . Memantine (Namenda®) is allowed only when prescribed in combination with donepezil or rivastigmine transdermal system.
  • Age 55 to 85 inclusive
  • Patients must be living in the community
  • Patients must have an eligible informant or study partner (caregiver)
  • Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
  • obtained from both the patient and the caregiver

Exclusion criteria

Exclusion Criteria:

  • Patients with cardiac, hepatic or renal impairment
  • Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
  • Patients who are taking any drug other than donepezil or rivastigmine transdermal system for Alzheimer's disease, including olal rivastigmine (Exelon®), galantamine (Razadyne®)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
482 participants (actual)

Study arms

  • Experimental
    T-817MA-H

    224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.

    Drug: T-817MA-H

  • Experimental
    T-817MA-L

    224 mg T-817MA once daily

    Drug: T-817MA-L

  • Placebo comparator
    Placebo

    Placebo once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. ADAS-cog Change From Baseline to Week 52

    The ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Scores can range from 0 (best) to 70 (worse).

    Time frame: Baseline and 52 weeks

  2. CGIC

    The ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) is a validated categorical measure of change in the patient's clinical condition between baseline and follow-up visits. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). It is suggested that the instrument has distinct clinical utility in assessing change in AD clinical trials.

    Time frame: 52 weeks

Secondary outcomes

  1. ADCS-ADL Change From Baseline to Week 52

    The ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) is a validated tool for assessing instrumental and basic activities of daily living based on a 23-item structured interview of the study partner. The scale has a range of 0 to 78, with lower scores indicating greater impairment.

    Time frame: Baseline and 52 weeks

07

Results

Posted Aug 9, 2018

Participant flow

Participant flow — Overall Study
MilestoneT-817MA-HT-817MA-LPlacebo
Started158166158
Completed120117140
Not completed384918
Withdrew: Adverse event23237
Withdrew: Withdrawal by subject9174
Withdrew: Lost to follow-up231
Withdrew: Death220
Withdrew: Lack of efficacy001
Withdrew: Protocol violation011
Withdrew: Physician decision011
Withdrew: Relocation etc.223

Outcome measures

PrimaryADAS-cog Change From Baseline to Week 52

The ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Scores can range from 0 (best) to 70 (worse).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · units on a scale
ADAS-cog Change From Baseline to Week 52
units on a scaleT-817MA-HT-817MA-LPlacebo
ADAS-cog Change From Baseline to Week 527.08 ± 0.7567.45 ± 0.7567.91 ± 0.727
Statistical analysis
  • T-817MA-H vs Placebo · Mixed Models Analysis · p = 0.3919 · Mean difference (final values): -0.84
PrimaryCGIC

The ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) is a validated categorical measure of change in the patient's clinical condition between baseline and follow-up visits. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). It is suggested that the instrument has distinct clinical utility in assessing change in AD clinical trials.

Time frame:
52 weeks
Reported as:
Mean · units on a scale
CGIC
units on a scaleT-817MA-HT-817MA-LPlacebo
CGIC5.25 ± 0.15.24 ± 0.15.22 ± 0.1
Statistical analysis
  • T-817MA-H vs Placebo · Mixed Models Analysis · p = 0.7588 · Mean difference (final values): 0.04
SecondaryADCS-ADL Change From Baseline to Week 52

The ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) is a validated tool for assessing instrumental and basic activities of daily living based on a 23-item structured interview of the study partner. The scale has a range of 0 to 78, with lower scores indicating greater impairment.

Time frame:
Baseline and 52 weeks
Reported as:
Mean · units on a scale
ADCS-ADL Change From Baseline to Week 52
units on a scaleT-817MA-HT-817MA-LPlacebo
ADCS-ADL Change From Baseline to Week 52-10.01 ± 0.991-11.07 ± 0.992-11.29 ± 0.957
Statistical analysis
  • T-817MA-H vs Placebo · Mixed Models Analysis · p = 0.3212 · Mean difference (final values): 1.29

Adverse events

Collected over 52weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-817MA-H2/158 (1.3%)26/158 (16.5%)132/158 (83.5%)
T-817MA-L2/166 (1.2%)25/166 (15.1%)133/166 (80.1%)
Placebo0/158 (0%)20/158 (12.7%)119/158 (75.3%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventT-817MA-HT-817MA-LPlacebo
SyncopeNervous system disorders0/1582/1663/158
DeliriumPsychiatric disorders3/1581/1661/158
CellulitisInfections and infestations2/1580/1660/158
Urinary Tract InfectionInfections and infestations2/1581/1661/158
DehydrationMetabolism and nutrition disorders2/1582/1660/158
Chest PainGeneral disorders0/1582/1661/158
SepsisInfections and infestations0/1582/1660/158
Anaemia MacrocyticBlood and lymphatic system disorders1/1580/1660/158
Acute Myocardial InfarctionCardiac disorders0/1580/1661/158
Atrial FibrillationCardiac disorders0/1580/1661/158
Most frequent other events
Showing 10 of 12
Most frequent other events
EventT-817MA-HT-817MA-LPlacebo
DiarrhoeaGastrointestinal disorders49/15834/16620/158
Urinary tract infectionInfections and infestations21/15817/16622/158
FallInjury, poisoning and procedural complications12/15814/16617/158
HeadacheNervous system disorders9/15816/16610/158
AgitationPsychiatric disorders4/1585/16614/158
NauseaGastrointestinal disorders9/15813/1666/158
AnxietyPsychiatric disorders7/1589/16612/158
DizzinessNervous system disorders11/1587/1663/158
NasopharyngitisInfections and infestations4/1584/1669/158
VomitingGastrointestinal disorders9/1588/1667/158

Baseline characteristics

The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.

Age, Continuous
Age, Continuous(years)T-817MA-HT-817MA-LPlaceboTotal
Mean71.8 ± 7.871.9 ± 8.271.8 ± 7.571.9 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)T-817MA-HT-817MA-LPlaceboTotal
Female828189252
Male727867217
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T-817MA-HT-817MA-LPlaceboTotal
American Indian or Alaska Native0101
Asian3328
Native Hawaiian or Other Pacific Islander1001
Black or African American871126
White140146142428
More than one race0112
Unknown or Not Reported2103
ApoE4 genotype
ApoE4 genotype(Participants)T-817MA-HT-817MA-LPlaceboTotal
Non-carriers545750161
Heterozygotes557471200
Homozygotes32212780
Unknown137828
MMSE
MMSE(units on a scale)T-817MA-HT-817MA-LPlaceboTotal
Mean18.4 ± 3.918.2 ± 3.818.2 ± 3.818.3 ± 3.8
08

Study locations

50 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona, United States
  • University of Arizona Health Sciences Center
    Tucson, Arizona, United States
  • Neurology Center of North Orange County
    Fullerton, California, United States
  • UCSD Comprehensive Alzheimer's Program
    La Jolla, California, United States
  • UC Irvine Medical Center
    Orange, California, United States
  • Geriatric and Adult Psychiatry, LCC
    Hamden, Connecticut, United States
  • Yale University, Alzheimer's Disease Research Unit
    New Haven, Connecticut, United States
  • Research Center for Clinical Studies, Inc.
    Norwalk, Connecticut, United States
  • Georgetown University Clinical Research Unit
    Washington, District of Columbia, United States
  • Infinity Clinical Research, LLC
    Hollywood, Florida, United States
  • University of Miami Miller-School of Medicine
    Miami, Florida, United States
  • Scientific Clinical Research, Inc
    North Miami, Florida, United States
  • Renstar Medical Research
    Ocala, Florida, United States
  • Meridien Research
    Tampa, Florida, United States
  • Neuro Trials Research, Inc
    Atlanta, Georgia, United States
  • Rush University Medical Center
    Chicago, Illinois, United States
  • SIU School of Medicine
    Springfield, Illinois, United States
  • Indiana Medical Research
    Elkhart, Indiana, United States
  • Indiana University Health Partners, Adult Neurology Clinic
    Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa, United States
  • University of Kansas/Clinical and Translational Science Unit
    Fairway, Kansas, United States
  • University of Kentucky Sanders-Brown Center on Aging Clinic
    Lexington, Kentucky, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana, United States
  • Acadia Hospital
    Bangor, Maine, United States
  • Boston University Alzheimer's Disease Center
    Boston, Massachusetts, United States
  • University of Michigan Health System/ Michigan Clinical Research Unit
    Ann Arbor, Michigan, United States
  • Michigan State University
    East Lansing, Michigan, United States
  • Bronson Neurobehvioral Health
    Paw Paw, Michigan, United States
  • University of Nebraska Medical Center(Geri Psych)
    Omaha, Nebraska, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada, United States
  • Global Medical Institutes, LLC;Princeton Medical Institute
    Princeton, New Jersey, United States
  • Dent Neurologic Institute
    Amherst, New York, United States
  • Alzheimer's Disease Research Center of Mount Sinai
    New York, New York, United States
  • Columbia University Medical Center Sergievsky Center Taub Institute
    New York, New York, United States
  • The Nathan S. Kline Instituite for Psychiatric Research
    Orangeburg, New York, United States
  • University of Rochester Medical Center
    Rochester, New York, United States
  • SUNY Upstate Medical University
    Syracuse, New York, United States
  • Wake Forest University (WFU) School of Medicine
    Winston-Salem, North Carolina, United States
  • Case Western Reserve University/ University Hospitals Case Medical Center
    Beachwood, Ohio, United States
  • Tulsa Clinical Research, LLC
    Tulsa, Oklahoma, United States
  • Hospital at the University of Pennsylvania, Penn Memory Center
    Philadelphia, Pennsylvania, United States
  • University of Pittsburgh, Alzheimer Disease Research Center
    Pittsburgh, Pennsylvania, United States
  • Abington Neurological Associates, LTD.
    Willow Grove, Pennsylvania, United States
  • Roper St. Francis Healthcare
    Charleston, South Carolina, United States
  • Vanderbilt University Medical Center -VUIIS
    Nashville, Tennessee, United States
  • University of North Texas Health Science Center
    Fort Worth, Texas, United States
  • Houston Methodist Hospital
    Houston, Texas, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin, United States
  • Cary J. Kohlenberg MD., SC dba IPC Research
    Waukesha, Wisconsin, United States
09

References and documents

Publications

  • Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer's Disease Cooperative Study TCAD Study Group. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019 Nov 1;76(11):1330-1339. doi: 10.1001/jamaneurol.2019.1868. PubMed 31282954 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 3 months after primary completion. A results delay was requested in Feb 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 6, 2014
Start
Mar 2014
Primary completionActual
May 5, 2017
CompletionActual
May 5, 2017
Results delay requested
Feb 23, 2016
Results first posted
Aug 9, 2018
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02079909
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)
Responsible party
Sponsor
First posted
Mar 6, 2014
Start date
Mar 2014
Primary completion
May 5, 2017
Completion
May 5, 2017
Results posted
Aug 9, 2018
Last update
Feb 26, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T-817 maleate

Start the discussion